Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Nektar Therapeutics changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 123 | 1 | 135 | +13 |
| Shares | 113.0M | 2.90K | 135.5M | +22.5M (+19.9%) |
| Value | $105.5M | $2.00K | $168.0M | +$62.4M (+59.2%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (36)
Institutions that held Nektar Therapeutics at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (23)
Institutions that held Nektar Therapeutics at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Stonepine Capital Management, LLC | 3,480,409 | $3.25M |
| Lynx1 Capital Management LP | 2,068,842 | $1.93M |
| Assenagon Asset Management S.A. | 1,687,300 | $1.58M |
| Marshall Wace, LLP | 1,471,237 | $1.37M |
| Alyeska Investment Group, L.P. | 1,069,272 | $998.9K |
| Schonfeld Strategic Advisors LLC | 535,800 | $500.5K |
| AQR Capital Management LLC | 430,983 | $385.3K |
| Y-Intercept (Hong Kong) Ltd | 127,564 | $119.2K |
| Diversified Trust Co | 60,211 | $56.2K |
| Point72 Asia (Singapore) Pte. Ltd. | 60,064 | $56.1K |
| State Board of Administration of Florida Retirement System | 67,437 | $47.4K |
| Squarepoint Ops LLC | 38,781 | $36.2K |
| Lido Advisors, LLC | 30,660 | $28.6K |
| Algert Global LLC | 29,430 | $27.5K |
| SEI Investments Co | 23,000 | $21.5K |
| First Citizens Bank & Trust Co | 11,686 | $10.9K |
| Envestnet Portfolio Solutions, Inc. | 11,686 | $10.9K |
| GTS Securities LLC | 11,388 | $10.6K |
| First Manhattan Co | 500 | $467 |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 200 | $186 |
| Cubist Systematic Strategies, LLC | 40 | $37 |
| Assetmark, Inc | 22 | $21 |
| CWM, LLC | 250 | $0 |
Not filed for Q2 2024 yet (1)
Institutions that held Nektar Therapeutics at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Cutler Group LP | 2,900 | $2.00K |